News | May 10, 2024
Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
Open a printable version of this pageEmail the URL of this page to a friend
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
His resignation would be effective from March 18, 2024
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Abbott India has reported total income of Rs. 1535 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
